Our Pricing

Antiviral Treatment: Advantages and Disadvantages

Understanding the antiviral treatment advantages disadvantages UK patients face when considering prescription weight loss medication is essential for making informed healthcare decisions. At Cured Pharmacy, our UK-registered clinical team provides transparent guidance on GLP-1 receptor agonists, lipase inhibitors, and other licensed treatments, helping you weigh the benefits against potential risks before starting therapy.

Advantages of GLP-1 Receptor Agonist Treatments

GLP-1 receptor agonists like Mounjaro (tirzepatide), Wegovy (semaglutide), and Saxenda (liraglutide) represent the most clinically effective prescription weight loss treatments licensed by the MHRA in the UK. These injectable medications work by mimicking natural gut hormones that regulate appetite, slow gastric emptying, and improve insulin sensitivity [1].

In the SURPASS-2 trial, patients taking tirzepatide achieved an average body weight reduction of up to 22.5% over 72 weeks—substantially higher than conventional therapies [1]. Similarly, the STEP trials demonstrated that semaglutide produced average weight loss of 14.9% over 68 weeks when combined with lifestyle interventions [2]. These medications also improve cardiovascular risk markers, including blood pressure, lipid profiles, and HbA1c levels in patients with type 2 diabetes.

Beyond weight reduction, patients typically report significant improvements in quality of life, mobility, and obesity-related comorbidities. The once-weekly injection schedule for Mounjaro and Wegovy offers convenience compared to daily medications, and most patients find the subcutaneous administration straightforward after initial training from a healthcare professional.

Metabolic and Cardiovascular Benefits

Clinical evidence shows GLP-1 treatments provide benefits beyond weight loss alone. The SELECT trial demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in adults with established cardiovascular disease, leading to expanded MHRA licensing for cardiovascular risk reduction [3]. Patients often experience improved glycaemic control, reduced inflammation markers, and better long-term metabolic health when treatment is maintained alongside lifestyle modifications.

Disadvantages and Potential Side Effects of Injectable Weight Loss Treatments

While GLP-1 receptor agonists demonstrate superior efficacy, they carry a distinct side effect profile that UK prescribers carefully assess during clinical consultations. The most commonly reported adverse effects include gastrointestinal symptoms—nausea, vomiting, diarrhoea, and constipation—particularly during dose escalation phases [1][2].

Approximately 44% of patients in the STEP-1 trial experienced nausea, though symptoms typically diminish as the body adapts to treatment [2]. More serious but rare risks include pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in rodent studies but not conclusively demonstrated in humans). Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use these medications.

Cost represents another significant consideration. GLP-1 treatments require ongoing investment—Mounjaro starts from £135.00 per month at Cured Pharmacy, and therapy typically continues for 12-24 months or longer. Weight regain commonly occurs if treatment is discontinued without sustained lifestyle changes, meaning long-term commitment is essential for maintaining results. Injectable administration may also deter patients uncomfortable with self-injection, though this becomes routine for most individuals after initial guidance.

Contraindications and Patient Suitability

GLP-1 treatments are not suitable for everyone. UK prescribers will assess your medical history for contraindications including pregnancy, breastfeeding, severe gastrointestinal disease, or a history of eating disorders. Patients taking certain diabetes medications may require dose adjustments to prevent hypoglycaemia. A thorough clinical assessment ensures treatment safety and appropriateness for your individual circumstances.

Advantages of Orlistat-Based Weight Loss Treatments

Orlistat (available as prescription-strength 120mg Orlistat and Xenical, or over-the-counter 60mg Alli and Orlos) offers a non-systemic alternative for UK patients seeking weight loss support. As a lipase inhibitor, Orlistat works locally in the digestive tract by blocking approximately 25-30% of dietary fat absorption, reducing overall calorie intake without entering the bloodstream [4].

This mechanism provides distinct advantages for patients who prefer oral medication over injections or have contraindications to GLP-1 therapies. Orlistat has an established 25-year safety profile in the UK, with no systemic absorption meaning minimal drug interactions and suitability for patients with cardiovascular conditions, diabetes, or those taking multiple medications. The lower-dose 60mg formulation is available without prescription, offering accessible first-line support for individuals with a BMI of 28 or above.

Clinical trials demonstrate that Orlistat combined with reduced-calorie diets produces average weight loss of 5-10% over 12 months—modest compared to GLP-1 treatments but clinically meaningful for improving metabolic health [4]. Patients often appreciate the immediate feedback mechanism: consuming high-fat meals while taking Orlistat results in gastrointestinal effects that reinforce healthier eating behaviours, creating a built-in behavioural modification component.

Disadvantages of Orlistat Treatments

The primary disadvantage of Orlistat is its gastrointestinal side effect profile. Because unabsorbed fat passes through the digestive system, patients commonly experience oily stools, flatulence with discharge, faecal urgency, and increased bowel movements—particularly when dietary fat intake exceeds recommended levels (typically 15g per meal) [4].

These effects, while not medically dangerous, can significantly impact quality of life and social confidence. Approximately 15-30% of patients discontinue Orlistat due to tolerability issues. The medication also reduces absorption of fat-soluble vitamins (A, D, E, K), requiring patients to take a daily multivitamin supplement at least two hours before or after Orlistat doses to prevent deficiency.

Efficacy is modest compared to newer treatments—average weight loss with Orlistat is approximately one-third of that achieved with GLP-1 receptor agonists in head-to-head comparisons. The three-times-daily dosing schedule (taken with each main meal) requires consistent adherence, and the treatment only works when dietary fat is present, making it less effective for patients following very low-fat diets. Success depends heavily on simultaneous dietary modification, meaning Orlistat functions as a support tool rather than a standalone solution.

Comparing Treatment Advantages and Disadvantages: Making an Informed Choice

When evaluating antiviral treatment advantages disadvantages UK patients should consider efficacy, tolerability, cost, administration method, and long-term sustainability. GLP-1 receptor agonists deliver superior weight loss outcomes and cardiovascular benefits but require injection, carry higher costs, and may cause significant nausea during initial weeks. Orlistat offers oral convenience and established safety but produces modest results and gastrointestinal side effects that some patients find intolerable.

Your individual circumstances—including BMI, comorbidities, previous weight loss attempts, budget, and personal preferences—should guide treatment selection in consultation with a UK prescriber. Patients with BMI over 35 or obesity-related complications typically benefit most from GLP-1 therapies, while those seeking first-line support or preferring non-injection options may find Orlistat appropriate. Some individuals achieve success by starting with Orlistat and progressing to GLP-1 treatments if additional support is needed.

At Cured Pharmacy, our clinical team conducts comprehensive assessments to recommend the most suitable option based on your medical history and weight loss goals. All prescription treatments require approval from a UK-registered prescriber following a free online consultation that takes under three minutes to complete. We provide transparent upfront pricing and dispense only genuine UK-licensed medications, ensuring you receive safe, effective treatment with ongoing clinical support.

Combining Medication with Lifestyle Interventions

Regardless of which treatment you choose, clinical trials consistently show that combining medication with reduced-calorie diets and increased physical activity produces significantly better outcomes than medication alone [1][2][4]. UK prescribers recommend aiming for a 500-600 calorie daily deficit, incorporating at least 150 minutes of moderate-intensity exercise weekly, and addressing behavioural factors that contribute to weight gain. Prescription weight loss medications are licensed as adjuncts to lifestyle modification, not replacements for healthy habits.

Starting Treatment: What to Expect from Your Clinical Assessment

Before prescribing any weight loss medication, UK regulations require a clinical assessment by a registered prescriber to ensure treatment safety and appropriateness. At Cured Pharmacy, this process begins with a confidential online consultation reviewing your medical history, current medications, weight loss goals, and any contraindications. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical services, ensuring every assessment meets GPhC and MHRA standards.

The consultation evaluates your BMI, obesity-related health conditions (such as type 2 diabetes, hypertension, or sleep apnoea), previous weight loss attempts, and lifestyle factors. For GLP-1 treatments, prescribers assess cardiovascular risk, thyroid history, and gastrointestinal conditions. For Orlistat, they review fat-soluble vitamin status and bowel function. This thorough evaluation identifies the most appropriate treatment while minimising risks.

Once approved, your medication is dispensed from our UK-registered pharmacy (GPhC 9012511) with discreet packaging and clear administration instructions. First-time users of injectable treatments receive detailed guidance on injection technique, pen operation, and dose escalation schedules. Follow-up support is available via phone (+44 116 4646009) or online consultation if you experience side effects or have questions during treatment. Regular monitoring helps optimise outcomes and adjust therapy as needed to achieve your weight loss goals safely and effectively.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., ... & Ryan, D. H. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
4. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment and lifestyle modifications.